| Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA JA Kyte, L Mu, S Aamdal, G Kvalheim, S Dueland, M Hauser, ... Cancer gene therapy 13 (10), 905-918, 2006 | 250 | 2006 |
| Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial PF Brunsvig, JA Kyte, C Kersten, S Sundstrøm, M Møller, M Nyakas, ... Clinical Cancer Research 17 (21), 6847-6857, 2011 | 208 | 2011 |
| Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma AB Del Campo, JA Kyte, J Carretero, S Zinchencko, R Méndez, ... International journal of cancer 134 (1), 102-113, 2014 | 187 | 2014 |
| Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients LJ Mu, JA Kyte, G Kvalheim, S Aamdal, S Dueland, M Hauser, ... British journal of cancer 93 (7), 749-756, 2005 | 160 | 2005 |
| Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients JA Kyte, G Gaudernack, S Dueland, S Trachsel, L Julsrud, S Aamdal Clinical Cancer Research 17 (13), 4568-4580, 2011 | 152 | 2011 |
| An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment X Tekpli, T Lien, AH Røssevold, D Nebdal, E Borgen, HO Ohnstad, ... Nature communications 10 (1), 5499, 2019 | 149 | 2019 |
| Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model H Almåsbak, E Walseng, A Kristian, MR Myhre, EM Suso, LA Munthe, ... Gene therapy 22 (5), 391-403, 2015 | 138 | 2015 |
| Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up HO Ohnstad, E Borgen, RS Falk, TG Lien, M Aaserud, MAT Sveli, JA Kyte, ... Breast Cancer Research 19, 1-12, 2017 | 118 | 2017 |
| Cancer vaccination with telomerase peptide GV1001 JA Kyte Expert opinion on investigational drugs 18 (5), 687-694, 2009 | 115 | 2009 |
| Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells JA Kyte, G Gaudernack Cancer Immunology, Immunotherapy 55, 1432-1442, 2006 | 106 | 2006 |
| Intrinsic functional potential of NK-cell subsets constrains retargeting driven by chimeric antigen receptors VYS Oei, M Siernicka, A Graczyk-Jarzynka, HJ Hoel, W Yang, D Palacios, ... Cancer immunology research 6 (4), 467-480, 2018 | 83 | 2018 |
| Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination JA Kyte, G Kvalheim, S Aamdal, S Sæbøe-Larssen, G Gaudernack Cancer gene therapy 12 (6), 579-591, 2005 | 76 | 2005 |
| T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells JA Kyte, G Kvalheim, K Lislerud, P thor Straten, S Dueland, S Aamdal, ... Cancer immunology, immunotherapy 56, 659-675, 2007 | 75 | 2007 |
| Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination JA Kyte, S Trachsel, B Risberg, P thor Straten, K Lislerud, G Gaudernack Cancer immunology, immunotherapy 58, 1609-1626, 2009 | 58 | 2009 |
| Resting small B cells present endogenous immunoglobulin variable‐region determinants to idiotope‐specific CD4+ T cells in vivo LA Munthe, JA Kyte, B Bogen European journal of immunology 29 (12), 4043-4052, 1999 | 58 | 1999 |
| Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells JA Kyte, S Aamdal, S Dueland, S Sæbøe-Larsen, EM Inderberg, ... Oncoimmunology 5 (11), e1232237, 2016 | 48 | 2016 |
| Non‐small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease HA Eide, AR Halvorsen, V Sandhu, A Fåne, J Berg, VD Haakensen, ... Clinical & Translational Immunology 5 (11), e109, 2016 | 47 | 2016 |
| Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination GL Hansen, G Gaudernack, PF Brunsvig, M Cvancarova, JA Kyte Cancer immunology, immunotherapy 64, 1609-1621, 2015 | 47 | 2015 |
| Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics S Jabeen, JA Espinoza, LA Torland, M Zucknick, S Kumar, ... Oncoimmunology 8 (2), e1537691, 2019 | 37 | 2019 |
| ICON: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer JA Kyte, NK Andresen, HG Russnes, SØ Fretland, RS Falk, OC Lingjærde, ... Journal of Translational Medicine 18, 1-10, 2020 | 36 | 2020 |
